Company: BLCO
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001860742-25-000004
Chunk: 73

Company: Bausch & Lomb Corp
Filing Date: 2025-02-19
Form: 10-K
Item: Item 7A
Chunk 73
---
 net of costs to sell2 1 — Interest settlements from cross-currency swaps13 13 — Net cash used in investing activities(412)(2,109)(215)Cash Flows From Financing Activities  Issuance of long-term debt, net of discounts631 2,276 2,440 Repayments of debt(430)(161)(13)Payment of employee withholding taxes related to share-based awards(12)(10)— Payments of financing costs— (16)(3)Payments of noncontrolling interest distributions(10)(9)(11)Net borrowings under BHC pooled financing arrangements (Note 3)— — 31 Net transfers to BHC (Note 3)— — (2,363)Other(1)(2)— Net cash provided by financing activities178 2,078 81 Effect of exchange rate changes on cash and cash equivalents and restricted cash(16)2 (8)Net (decrease) increase in cash and cash equivalents and restricted cash(18)(46)203 Cash and cash equivalents and restricted cash, beginning of period334 380 177 Cash and cash equivalents and restricted cash, end of period$316 $334 $380 Non-cash Financing ActivityAccrued purchases of property, plant and equipment$56 $65 $38 Issuance of BHC Purchase Debt (Note 3)$— $— $2,200 The accompanying notes are an integral part of these consolidated financial statements.

F-9

BAUSCH + LOMB CORPORATIONNOTES TO CONSOLIDATED FINANCIAL STATEMENTS1.DESCRIPTION OF BUSINESSOverviewBausch + Lomb Corporation (“Bausch + Lomb” or the “Company”) is a leading global eye health company dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. The Company operates in three reportable segments: (i) Vision Care segment which includes both a contact lens business and a consumer eye care business that consists of contact lens care products, over-the-counter (“OTC”) eye drops and eye vitamins, (ii) Pharmaceuticals segment which consists of a broad line of proprietary and generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases and (iii) Surgical segment which consists of medical device equipment, consumables,